RIXUBIS PMS India (RIXUBIS PMS)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-07

Study Completion Date

2021-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to characterize the safety and describe the effectiveness of RIXUBIS in routine clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

NCT02922231

Hemophilia B

COMPLETED

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723

Severe Hemophilia B

COMPLETED PHASE3

RIXUBIS Drug Use-Result Survey (Japan)

NCT02937831

Hemophilia B

COMPLETED

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

NCT03875547

Haemophilia B

ENROLLING_BY_INVITATION

Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

NCT02336178

HEMOPHILIA B

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Study Participants

Study participants with Hemophilia B in India receiving Rixubis

Group Type EXPERIMENTAL

RIXUBIS: On-Demand

Intervention Type BIOLOGICAL

RIXUBIS used under standard clinical practice in India: On-Demand treatment.

RIXUBIS: Prophylaxis

Intervention Type BIOLOGICAL

RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RIXUBIS: On-Demand

RIXUBIS used under standard clinical practice in India: On-Demand treatment.

Intervention Type BIOLOGICAL

RIXUBIS: Prophylaxis

RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BAX326 Recombinant Factor IX rFIX Coagulation Factor IX [Recombinant] rFactor IX BAX 326 BAX326 Recombinant Factor IX rFIX Coagulation Factor IX [Recombinant] rFactor IX BAX 326

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant or legally authorized representative (in case of study participants \<18 years of age) gave written informed consent to participate in the study.
2. Participant has hemophilia B.
3. Participant is defined as previously-treated patient (PTP):

* Participant aged ≥ 6 years that has been previously treated with plasma-derived and/or recombinant factor IX (FIX) concentrate(s) for a minimum of 150 exposure days (EDs).
* Participant aged \< 6 years that has been previously treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 50 EDs.
4. Participant has no evidence of a history of FIX inhibitors.
5. Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable disease and CD4+ count ≥ 200 cells/mm\^3, as confirmed by central laboratory at screening.
6. Participant is hepatitis C virus negative (HCV-) by antibody or PCR testing (if positive, antibody titer will be confirmed by polymerase chain reaction (PCR)), as confirmed by central laboratory at screening; or HCV+ with chronic stable hepatitis.
7. The participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria

1. Participant has known hypersensitivity or presence of any contraindication to RIXUBIS or its excipients including hamster protein.
2. Participant has evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).
3. Participant has a history of FIX inhibitors with a titer ≥ 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay, employed in the respective local laboratory) at any time prior to screening.
4. Participant has a detectable FIX inhibitor at screening, with a titer ≥ 0.6 BU as determined by the Nijmegen modification of the Bethesda assay in the central laboratory.
5. Participant has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) \> 1.4 hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
6. Participant has severe chronic hepatic dysfunction \[eg, ≥ 5 times upper limit of normal alanine aminotransferase (ALT), as confirmed by central laboratory at screening, or a documented INR \> 1.5\].
7. Participant has severe renal impairment (serum creatinine \> 2.0 mg/dL), as confirmed by central laboratory at screening.
8. Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia B.
9. Participant's platelet count is \< 100,000/mL.
10. Participant has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect participant's safety or compliance.
11. Participant is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug (eg, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day, or α-interferon) other than antiretroviral chemotherapy.
12. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
13. Participant is a family member or employee of the investigator.

Eligible Sex

ALL

Accepts Healthy Volunteers

No